Amgen Inc. (NASDAQ: AMGN) just delivered a strong beat-and-raise quarter. That’s pushed the stock to within striking distance of its 52-week high. That also puts it within striking distance of a new all-time high when adjusted for the company’s five stock splits since its initial public offering in 1990.
The company is showing strength across every segment of its drug portfolio. That strength is reflected in the headline numbers. Revenue of $9.56 billion came in 6.89% higher than the forecast of $8.97 billion. It was also higher than the $8.50 billion the company earned in the same quarter in 2024.
